Last reviewed · How we verify
Intravenous Sodium Valproate
At a glance
| Generic name | Intravenous Sodium Valproate |
|---|---|
| Also known as | DEPAKINE® |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc Displacement (PHASE2)
- Antiseizure Medication in Seizure Networks at Early Acute Brain Injury (PHASE4)
- Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial) (PHASE3)
- Sodium Valproate in Patients With Acute Ischemic Stroke (PHASE2)
- Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium (PHASE4)
- A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures (PHASE1, PHASE2)
- Efficacy Study of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus. (NA)
- Effect of Valproic Acid Concentration on Photic Response (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Sodium Valproate CI brief — competitive landscape report
- Intravenous Sodium Valproate updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI